This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Frequency Therapeutics Dividenden en inkoop

Dividend criteriumcontroles 0/6

Frequency Therapeutics heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

-0.006%

Terugkoop Rendement

Totaal aandeelhoudersrendement	-0.006%
Toekomstig dividendrendement	n/a
Dividendgroei	n/a
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	n/a

Recente updates van dividend en inkoop

Geen updates

Recent updates

Analyseartikel • Jan 01

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analyseartikel • Jan 19

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Analyseartikel • Aug 18

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Market forces rained on the parade of Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) shareholders today, when the...

Analyseartikel • Jul 31

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analyseartikel • Apr 04

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Today is shaping up negative for Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) shareholders, with the analysts...

Analyseartikel • Mar 15

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Frequency...

Analyseartikel • Jan 22

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than...

Analyseartikel • Dec 27

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Some Frequency Therapeutics, Inc. ( NASDAQ:FREQ ) shareholders may be a little concerned to see that the Independent...

Analyseartikel • Dec 10

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

Analyseartikel • Nov 19

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) investors will be delighted, with the company turning in some strong...

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van FREQ in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van FREQ zijn gestegen.

Dividendrendement versus markt

Frequency Therapeutics Dividendrendement versus markt

Hoe verhoudt FREQ dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (FREQ)	n/a
Markt onderkant 25% (US)	1.4%
Markt Top 25% (US)	4.2%
Gemiddelde industrie (Biotechs)	2.4%
Analist prognose (FREQ) (tot 3 jaar)	n/a

Opmerkelijk dividend: Het dividendrendement van FREQ kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van FREQ kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio FREQ te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat FREQ geen uitbetalingen heeft gerapporteerd.

Ontdek bedrijven met een sterk dividend

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2023/11/05 10:30
Aandelenkoers aan het einde van de dag	2023/11/03 00:00
Inkomsten	2023/09/30
Jaarlijkse inkomsten	2022/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Frequency Therapeutics, Inc. wordt gevolgd door 7 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Jack Allen	Baird
Mayank Mamtani	B. Riley Securities, Inc.
Daniil Gataulin	Chardan Capital Markets, LLC

This company is no longer active

Frequency Therapeutics Dividenden en inkoop

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente updates van dividend en inkoop

Recent updates

Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders.

New major risk - Market cap size

Insufficient new directors

New major risk - Financial position

Frequency Therapeutics, Inc. Announces the Resignation of Christopher Loose as Chief Scientific Officer

New major risk - Share price stability

Korro Bio, Inc. entered into a definitive merger agreement to acquire Frequency Therapeutics, Inc. (NasdaqGS:FREQ) from a group of shareholders in a reverse merger transaction.

Frequency Therapeutics, Inc. Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?

Frequency Therapeutics, Inc. Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

Price target decreased to US$6.67

Frequency Therapeutics, Inc. Completes Enrollment of Phase 2B Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 2500 Index

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Frequency Therapeutics, Inc., Annual General Meeting, Jun 21, 2022

Price target decreased to US$12.00

Insufficient new directors

Frequency Therapeutics, Inc. Announces Peter P. Pfreundschuh Stepping Down as Chief Financial Officer

Price target increased to US$14.33

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?

Insufficient new directors

Frequency Therapeutics, Inc. Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise

Frequency Therapeutics, Inc. Announces New FX-322 Results Showing that Additional Study Participants Gain Hearing Improvements at Later Time Points

Price target decreased to US$12.75

Consensus revenue estimates fall to US$36.2m

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year

Second quarter 2021 earnings released: US$0.52 loss per share (vs US$0.19 loss in 2Q 2020)

Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?

Lieff Cabraser Heimann & Bernstein, LLP Announces That Class Action Litigation Has Been Filed Against Frequency Therapeutics, Inc

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 2500 Growth Index

Co-Founder exercised options to buy US$1.1m worth of stock.

Rosen Law Firm Encourages Frequency Therapeutics, Inc. Investors with Losses Exceeding $100,000 to Secure Counsel Before Important Deadline

Price target decreased to US$14.25

Consensus forecasts updated

Forecast to breakeven in 2025

Insider recently bought US$89k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.60 loss per share (vs US$0.16 loss in 1Q 2020)

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be

Full year 2020 earnings released: US$0.82 loss per share (vs US$2.29 loss in FY 2019)

Independent Director exercised options to buy US$316k worth of stock.

We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn

Co-­Founder exercised options and sold US$469k worth of stock

Frequency Therapeutics, Inc. Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322

New 90-day high: US$54.87

Frequency Therapeutics, Inc. Appoints Kevin Franck as Senior Vice President of Strategic Marketing and New Product Planning

Co-­Founder exercised options and sold US$385k worth of stock

New 90-day high: US$40.50

If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns

Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer

Co-­Founder exercised options and sold US$594k worth of stock

Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?

Independent Director recently sold US$1.7m worth of stock

Frequency Therapeutics, Inc. Enters into an Agreement for Termination of Lease and Voluntary Surrender of Premises

Price target raised to US$36.33

Co-­Founder exercised options and sold US$437k worth of stock

How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?

New 90-day high: US$28.86

Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer

Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Third quarter 2020 earnings released: US$0.16 loss per share

Revenue beats expectations, earnings disappoint

Co­-Founder & Chief Scientific Officer notifies of intention to sell stock

New 90-day high: US$25.05

Frequency Therapeutics Appoints Cynthia Feldmann to Its Board of Directors

Frequency Therapeutics, Inc. Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss

New 90-day high: US$24.96

Frequency Therapeutics, Inc. announced that it has received $42.301944 million in funding from a group of investors

Frequency Therapeutics, Inc. announced that it expects to receive $42.301944 million in funding from a group of investors

Frequency Therapeutics, Inc.(NasdaqGS:FREQ) dropped from Russell 3000 Value Index

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Co-Founder exercised options and sold US$469k worth of stock

Co-Founder exercised options and sold US$385k worth of stock

Co-Founder exercised options and sold US$594k worth of stock

Co-Founder exercised options and sold US$437k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock